News & Updates
Excerpt from the Press Release: BOSTON, Feb. 27, 2026 /PRNewswire/ — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced results from the first head-to-head study comparing urinary bladder radioactivity between two prostate-specific membrane antigen (PSMA)-targeted PET radiopharmaceuticals. This prospective, multicenter,…
Excerpt from the Press Release: MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that enrollment is now complete for the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP). As a one-year clinical trial,…
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable to Placebo; Pharmacokinetic Profile Supports Once-Daily Oral Dosing Phase 2 Development Planned to Begin with Chronic Spontaneous Urticaria in the Second Half…
New Toolkit Allows Researchers to Test Potential Cancer Targets Directly in Patient-Leukemia Cells Excerpt from the Press Release: PHILADELPHIA, Feb. 26, 2026 /PRNewswire/ — A new CRISPR-based tool that is directly used on patients’ cancer cells can identify genes and regulatory elements driving acute myeloid leukemia (AML), an aggressive blood cancer affecting the bone marrow and…
Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles Excerpt from the Press Release: (Boston, MA – 26 February, 2026) Curium, a world leading nuclear medicine company dedicated to using cutting-edge technology and innovative science to personalize diagnoses and treatments…
Join Christopher Kata, Director of Sales & Marketing, and Nick Travers, Business Development Director, at ACDM 2026 in Berlin Germany, from March 15-17! If you plan to attend, we invite you to connect with Christopher and Nick to schedule a one‑on‑one meeting, or feel free to visit our booth at your convenience. We look forward…
Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses from the Phase 3 OASIS-HAE and OASISplus studies. Results will be presented at the 2026 American Academy of Allergy, Asthma…
– Onvuzosiran achieved significant and durable reductions of plasma kallikrein levels with a favorable safety profile in Phase 1/2 – – Positive results support ongoing Phase 3 clinical trial – Excerpt from the Press Release: SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics,…
– Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months – – Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial…
95% of Participants Demonstrated Clinical Improvement with No Device-Related Serious Adverse Events Through 90-Day Follow-Up Excerpt from the Press Release: BOSTON, Feb. 24, 2026 /PRNewswire/ — CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, today announced results from a prospective, multi-center, single-arm clinical study evaluating the safety and clinical outcomes…
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?